About Us

Coulter Partners is a global search specialist focused exclusively on life sciences. The firm is held in the highest regard as trusted adviser to the sector on senior leadership roles in the American, U.K. and European Markets.

They have a combined expertise gained over 25 years in the industry, concentrated in the largest dedicated Life Sciences team in North America and Europe. 75 consultants work together as a single global P&L from 10 offices; 5 of these are in the US and 5 in Europe.

The firm’s approach is to hire and develop exceptional multi-skilled sector analysts with PhDs, MBAs, deep industry knowledge and an outstanding track record of search at Executive and Board level. Its team culture and personal reward system are founded on commitment to the highest standards of client and candidate service.

Their mission is to impact the industry’s ability to deliver advances in diagnosis, prevention, treatment and management of disease. They do this by bringing the world’s best talent to a broad spectrum of global clients; from multinationals, to small and midcap businesses, as well as to the global investor community, building their own teams and the boards and executive leadership of their portfolio investments.

Achievements

Find a Recruiter

17

At the heart of everything they do Coulter Partners is an exceptional team of talented individuals. Multi-disciplined, passionate and committed to being the best, they have PhDs, MBAs and speak many languages. Every challenge is approached with a blend of innovative thinking and best-in-class search methodology. There are no barriers to sharing information and everyone is rewarded for quality delivery. Exchanging knowledge, experience and data brings mutual support. Success follows naturally.

Solutions And Expertise

Coulter Partners is a global search specialist focused exclusively on life sciences. The firm is held in the highest regard as trusted adviser to the sector on senior leadership roles in the American, U.K. and European Markets.

Solutions
  • Executive Search
Industries
Functions
  • CEO/President
  • Finance/Accounting
  • Human Resources
  • Marketing & Sales

News Briefings

Coulter Partners Recruits Chief Scientific Officer for CENTOGENE      

With the integration of technology into all facets of everyday life, the life sciences and healthcare industry is hardly alone in facing technology-related issues. These take on increased importance when they impact health, disease diagnosis, treatment and, ultimately, human longevity. Having the right leaders in place to sort through these complex challenges, say recruiters serving

Coulter Partners Recruits CFO for Stilla Technologies

Life sciences-focused executive search firm Coulter Partners placed Khaled Bahi as the new CFO of Paris-based Stilla Technologies. Client partner Eskil Westh led the assignment. Mr. Bahi’s appointment comes at a time of rapid growth for the company, with the recent opening of a U.S. subsidiary headquartered in Beverly, MA, providing American customers with direct sales and

Coulter Partners Finds Chief Scientific Officer for OxStem

With the integration of technology into all facets of everyday life, the life sciences and healthcare industry is hardly alone in facing technology-related issues. These take on increased importance when they impact health, disease diagnosis, treatment and, ultimately, human longevity. Having the right leaders in place to sort through these complex challenges, say recruiters serving

Coulter Partners Opens New Office in Brussels, Expands Search Staff

Life sciences-focused executive search firm Coulter Partners has expanded with the opening of a new office in Brussels and six recent appointments. Penny Sadler joins the firm’s medtech expertise as client partner in Brussels, while Nanna Soni is appointed director in London to the R&D center of expertise. The Paris office expands with the additions of Nicolas

Press Releases

Coulter Partners secures Chief Financial Officer for Stilla Technologies

LONDON, UK., January 2020 – Coulter Partners was delighted to partner recently with Stilla Technologies, provider of pioneering digital PCR (dPCR) solutions for high-precision genetic analysis, to secure the appointment of Khaled Bahi as Chief Financial Officer. His appointment comes at a time of rapid growth for the company, with the recent opening of a U.S.

Coulter Partners Secures Vice President of Finance for Pivot Bio

LONDON, U.K., April 2019 – Coulter Partners has partnered again with Pivot Bio, an agriculture technology company based in Silicon Valley, to secure the appointment of Christa Peren as Vice President of Finance. Christa Peren joined Pivot Bio as VP-Finance in February 2019, bringing more than 25 years of business finance experience to the role.

Coulter Partners Secures new Country Manager for AniCura in DACH

LONDON, U.K., February 2019 – Coulter Partners was delighted to partner with international veterinary care provider, AniCura, to secure the appointment of Carla Naumann as the new Country Manager in Germany, Austria & Switzerland (DACH). Carla has some 20 years’ experience of various managerial roles within the healthcare sector in Germany and abroad. The recruitment

Coulter Partners Secures Chief of Business Operations for Nanoform

LONDON, U.K., January 2019 – Coulter Partners was very pleased to partner once again with innovative drug enabling nanotechnology company, Nanoform to secure the appointment of Dr. Gonçalo Rebelo de Andrade as Chief of Business Operations. The newly created role will significantly strengthen Nanoform’s commercial organization and continue its rapid growth through international sales. The

Coulter Partners secures Vice President, Corporate Development & Strategy for Zumutor Biologics

LONDON, U.K., – Coulter Partners was delighted to partner with Zumutor Biologics, a leading Immuno-Oncology Company in the targeted NK cell therapeutics space, to secure the appointment of Ramon Valencia as Vice President, Corporate Development and Strategy. Ramon will help build on Zumutor’s key successes that include proprietary antibody discovery platforms and a compelling pipeline of